RCKT
Rocket Pharmaceuticals, Inc. [RCKT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RCKT Stock Summary
Top 10 Correlated ETFs
RCKT
Top 10 Correlated Stocks
RCKT
In the News
RCKT Financial details
RCKT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.7 | -2.65 | -2.68 | -3.22 | -2.92 | |
| Operating cash flow per share | -1.32 | -1.35 | -1.92 | -2.61 | -2.32 | |
| Free cash flow per share | -1.79 | -1.87 | -2.04 | -2.74 | -2.52 | |
| Cash per share | 6.21 | 8.72 | 6.15 | 5.23 | 4.44 | |
| Book value per share | 6.27 | 9.09 | 7.19 | 7.19 | 5.86 | |
| Tangible book value per share | 5.64 | 8.54 | 6.7 | 6.23 | 5.1 | |
| Share holders equity per share | 6.27 | 9.09 | 7.19 | 7.19 | 5.86 | |
| Interest debt per share | 1.07 | 1.25 | 0.45 | 0.36 | 0.32 | |
| Market cap | 1.12B | 3.04B | 1.38B | 1.33B | 2.52B | |
| Enterprise value | 977.54M | 2.8B | 1.17B | 1.22B | 2.49B | |
| P/E ratio | -13.4 | -20.71 | -8.14 | -6.08 | -10.25 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -17.25 | -40.69 | -11.39 | -7.49 | -12.92 | |
| PFCF ratio | -12.69 | -29.29 | -10.71 | -7.14 | -11.91 | |
| P/B Ratio | 3.63 | 6.03 | 3.04 | 2.72 | 5.11 | |
| PTB ratio | 3.63 | 6.03 | 3.04 | 2.72 | 5.11 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -13.57 | -21.39 | -7.17 | -5.69 | -9.85 | |
| EV to operating cash flow | -15.12 | -37.54 | -9.66 | -6.83 | -12.76 | |
| EV to free cash flow | -11.12 | -27.02 | -9.08 | -6.51 | -11.76 | |
| Earnings yield | -0.07 | -0.05 | -0.12 | -0.16 | -0.1 | |
| Free cash flow yield | -0.08 | -0.03 | -0.09 | -0.14 | -0.08 | |
| Debt to equity | 0.15 | 0.12 | 0.05 | 0.05 | 0.05 | |
| Debt to assets | 0.13 | 0.1 | 0.05 | 0.04 | 0.04 | |
| Net debt to EBITDA | 1.91 | 1.8 | 1.29 | 0.55 | 0.12 | |
| Current ratio | 16.81 | 14.94 | 17.69 | 9.29 | 7.8 | |
| Interest coverage | -15.92 | -17.8 | -28.4 | -117.52 | -138.48 | |
| Income quality | 0.84 | 0.53 | 0.72 | 0.8 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.04 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.08 | 0.05 | 0.06 | 0.12 | 0.11 | |
| Capex to operating cash flow | 0.36 | 0.39 | 0.06 | 0.05 | 0.08 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -54.62 | -25.38 | -1.44 | -1.38 | -2.32 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.48 | 23.28 | 20.83 | 22.81 | 19.64 | |
| ROIC | -0.23 | -0.24 | -0.34 | -0.41 | -0.48 | |
| Return on tangible assets | -0.24 | -0.26 | -0.36 | -0.45 | -0.49 | |
| Graham Net | 4.88 | 7.14 | 5.48 | 4.32 | 3.56 | |
| Working capital | 289.45M | 454.73M | 369.89M | 324.89M | 329.72M | |
| Tangible asset value | 276.26M | 472.7M | 423.91M | 424.81M | 428.27M | |
| Net current asset value | 242.93M | 400.04M | 349.76M | 301.94M | 304.46M | |
| Invested capital | 0.15 | 0.12 | 0.05 | 0.05 | 0.05 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 170 | 587.5 | 658.5 | 18.33M | 18.33M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0.29 | 0.27 | 0.03 | 2.14K | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.25K | 1.37K | 11.15K | 0.17 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.27 | -0.29 | -0.37 | -0.45 | -0.5 | |
| Capex per share | -0.47 | -0.52 | -0.12 | -0.13 | -0.2 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.11 | |
| Net income per share | -0.88 | -0.69 | -0.82 | -0.75 | -0.64 | |
| Operating cash flow per share | -0.77 | -0.72 | -0.63 | -0.69 | -0.31 | |
| Free cash flow per share | -0.81 | -0.76 | -0.68 | -0.75 | -0.36 | |
| Cash per share | 4.89 | 4.17 | 3.82 | 5.29 | 4 | |
| Book value per share | 6.72 | 5.78 | 5.01 | 6.55 | 5.28 | |
| Tangible book value per share | 5.83 | 4.96 | 4.2 | 5.77 | 4.59 | |
| Share holders equity per share | 6.72 | 5.78 | 5.01 | 6.55 | 5.28 | |
| Interest debt per share | 0.31 | 0.33 | 0.32 | 0.3 | 0.27 | |
| Market cap | 1.43B | 1.36B | 1.6B | 1.69B | 2.8B | |
| Enterprise value | 1.31B | 1.32B | 1.58B | 1.49B | 2.77B | |
| P/E ratio | -5.54 | -6.19 | -6.08 | -6.84 | -11.72 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 271.27 | |
| POCF ratio | -25.46 | -23.65 | -31.43 | -29.63 | -95.34 | |
| PFCF ratio | -24.06 | -22.47 | -29.06 | -27.4 | -82.31 | |
| P/B Ratio | 2.91 | 2.97 | 3.97 | 3.13 | 5.68 | |
| PTB ratio | 2.91 | 2.97 | 3.97 | 3.13 | 5.68 | |
| EV to sales | 0 | 0 | 0 | 0 | 268.27 | |
| Enterprise value over EBITDA | -20.46 | -23.52 | -24.87 | -22.81 | -48.32 | |
| EV to operating cash flow | -23.36 | -22.96 | -31.05 | -26.12 | -94.29 | |
| EV to free cash flow | -22.08 | -21.82 | -28.71 | -24.15 | -81.4 | |
| Earnings yield | -0.05 | -0.04 | -0.04 | -0.04 | -0.02 | |
| Free cash flow yield | -0.04 | -0.04 | -0.03 | -0.04 | -0.01 | |
| Debt to equity | 0.05 | 0.06 | 0.06 | 0.05 | 0.05 | |
| Debt to assets | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | |
| Net debt to EBITDA | 1.84 | 0.7 | 0.31 | 3.06 | 0.54 | |
| Current ratio | 9.29 | 10.83 | 9.09 | 13.35 | 7.8 | |
| Interest coverage | 112.51 | -132.89 | -146.92 | 139.51 | -134.64 | |
| Income quality | 0.84 | 0.99 | 0.77 | 0.92 | 0.49 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 2.09 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 4.05 | |
| Intangibles to total assets | 0.12 | 0.13 | 0.14 | 0.11 | 0.11 | |
| Capex to operating cash flow | 0.06 | 0.05 | 0.08 | 0.08 | 0.16 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.45 | |
| Capex to depreciation | -0.96 | -1.81 | -2.4 | -2.65 | -2.4 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.96 | |
| Graham number | 11.55 | 9.48 | 9.59 | 10.51 | 8.71 | |
| ROIC | -0.12 | -0.11 | -0.16 | -0.11 | -0.12 | |
| Return on tangible assets | -0.13 | -0.12 | -0.17 | -0.12 | -0.12 | |
| Graham Net | 4.04 | 3.46 | 3.08 | 4.59 | 3.21 | |
| Working capital | 324.89M | 306.83M | 277.73M | 413.39M | 329.72M | |
| Tangible asset value | 424.81M | 394M | 338.09M | 476.78M | 428.27M | |
| Net current asset value | 301.94M | 282.15M | 253.26M | 389.19M | 304.46M | |
| Invested capital | 0.05 | 0.06 | 0.06 | 0.05 | 0.05 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 18.33M | 18.33M | 1.39K | 1.48K | 926.5 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.86K | 0.09 | 0.06 | 0.09 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.05 | 1K | 1.54K | 950.35 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.13 | -0.12 | -0.16 | -0.11 | -0.12 | |
| Capex per share | -0.04 | -0.04 | -0.05 | -0.06 | -0.05 |
RCKT Frequently Asked Questions
What is Rocket Pharmaceuticals, Inc. stock symbol ?
Rocket Pharmaceuticals, Inc. is a US stock , located in Cranbury of Nj and trading under the symbol RCKT
What is Rocket Pharmaceuticals, Inc. stock quote today ?
Rocket Pharmaceuticals, Inc. stock price is $23.561 today.
Is Rocket Pharmaceuticals, Inc. stock public?
Yes, Rocket Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 724.23K
- Market Capitalization 2.19B
- Employee 268
- CEO Dr. Gaurav D. Shah M.D.
- Headquarters Cranbury,NJ,US
- IPO Date 2015-02-18
-
Website
https://rocketpharma.com 
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
